BioSpace News Archive

Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the three months ended March 31, 2021 on Thursday, April 29, 2021 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m.

VERITAS™ Vision System to introduce innovations in fluidics management and usability to fuel surgeons’ performance in every cataract procedure, from the easiest to most challenging

Rosacea sufferers join forces this Rosacea Awareness Month to bravely share the personal impact essential COVID-19 mask-wearing has on their skin condition

EdiGene, Inc., announced the successful completion of an RMB 400 million Series B Plus financing. Loyal Valley Capital led the round and other new investors included BioTrack Capital and Sherpa Healthcare Partners, along with continued support by existing investors including IDG Capital, Lilly Asia Venture, 3H Health Investment, Huagai Capital, Sequoia Capital China, Alwin Capital and Kunlun Capital.

A new collaboration will help oncologists learn whether Black and white cancer patients respond differently to a game-changing immunotherapy treatment, and seeks to improve the safety and effectiveness of these newer drugs in diverse populations.

Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will host a conference call and webcast to discuss its first quarter 2021 financial results on Wednesday, April 28, 2021 at 4:30 p.m. ET.

AGREEMENT ALLOWS CARDIOLOGISTS TO PERFORM DPR AND FFR PROCEDURES USING OPSENS’ OPTOWIRE AND CATHMEDICAL’S PICASSO SYSTEM IN AN INTEGRATED FASHION

- Key hires in clinical and CMC augment Nimbus’ in-house capabilities as a development-stage biotech -

Prelude Corporation (PreludeDx ™ ), a leader in molecular diagnostics and precision medicine for early stage breast cancer, announced results for a prospective study in 44 U.S. academic and community cancer centers that evaluated the impact of DCISionRT

- Anticipates Revenues in the Range of $2.5 Million to $2.7 Million Driven by COVID-19 Testing and Diagnostics Sales - - Announces Full Loan Forgiveness under Paycheck Protection Program – - NYS Department of Health Completes Re-Inspection of ADCL -